Since HD-IL2 is an immunotherapy and subsets of patients with RCC are responsive to IL2 and other I-O agents such as anti-programmed cell death-1 receptor or ligand (anti-PD-(L)1) antibodies, a select panel of immune gene signatures and individual genes were evaluated in the HD-IL2 pretreatment tumor specimens. This evidence concerns the gene IL2 and neoplasm.